Clinical Trial Update: A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports a Phase 2/3 study evaluating tinlarebant for Stargardt disease (STGD1), with the trial currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• Tinlarebant

Snippet

Sponsor: Belite Bio, Inc | Conditions: STGD1, Stargardt Disease 1 | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING